 LA JOLLA, Calif.--BUSINESS WIRE--- EQ--Equillium, Inc. Nasdaq: EQ, a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference, taking place February 14 18, 2022. Bruce Steel, Equilliums chief executive officer, and Steve Connelly Ph.D., Equilliums chief scientific officer, will pro 